U.S. patent application number 15/279120 was filed with the patent office on 2017-01-19 for method of preparing blastocysts for cryopreservation.
This patent application is currently assigned to Mariposa Biotechnology, Inc.. The applicant listed for this patent is Mariposa Biotechnology, Inc.. Invention is credited to Fred H. Burbank, Michael L. Jones.
Application Number | 20170013827 15/279120 |
Document ID | / |
Family ID | 41570583 |
Filed Date | 2017-01-19 |
United States Patent
Application |
20170013827 |
Kind Code |
A1 |
Burbank; Fred H. ; et
al. |
January 19, 2017 |
METHOD OF PREPARING BLASTOCYSTS FOR CRYOPRESERVATION
Abstract
An automated system and method of preparing oocytes, embryos, or
blastocysts for cryopreservation. The method entails delivering two
or more solutions into a container holding oocytes, embryos, or
blastocysts, and controlling the flow of the solutions to gradually
change the concentration of cryoprotectants and dehydrating agents
in the container to minimize shock to the oocytes, embryos or
blastocysts.
Inventors: |
Burbank; Fred H.; (San
Clemente, CA) ; Jones; Michael L.; (San Clemente,
CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Mariposa Biotechnology, Inc. |
San Clemente |
CA |
US |
|
|
Assignee: |
Mariposa Biotechnology,
Inc.
San Clemente
CA
|
Family ID: |
41570583 |
Appl. No.: |
15/279120 |
Filed: |
September 28, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15074531 |
Mar 18, 2016 |
9485984 |
|
|
15279120 |
|
|
|
|
13055134 |
May 12, 2011 |
|
|
|
PCT/US2009/051428 |
Jul 22, 2009 |
|
|
|
15074531 |
|
|
|
|
13055134 |
May 12, 2011 |
|
|
|
PCT/US09/51428 |
Jul 22, 2009 |
|
|
|
13055134 |
|
|
|
|
61116255 |
Nov 19, 2008 |
|
|
|
61083043 |
Jul 23, 2008 |
|
|
|
61116255 |
Nov 19, 2008 |
|
|
|
61083043 |
Jul 23, 2008 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A01N 1/0221 20130101;
A01N 1/0252 20130101 |
International
Class: |
A01N 1/02 20060101
A01N001/02 |
Claims
1. A method of preparing blastocysts for cryopreservation, said
method comprising: positioning one or more blastocysts in a
container; and flowing a first solution comprising a cryoprotectant
over the blastocysts by delivering the first solution into the
container and removing the first solution from the container, for a
first time period; while delivering the first solution into the
container, initiating flow of a second solution comprising a
dehydrating agent into the container; wherein the step of
initiating flow of the second solution is initiated while some of
the first solution is in the processing container, and accomplished
to gradually increase the concentration of the dehydrating agent in
the container.
2. The method of claim 1, wherein the concentration of the
cryoprotectant in the first solution is increased from about 0.0 M
to about 1.5 M during the first period.
3. The method of claim 1, wherein the concentration of the
dehydrating components in the second solution is increased from
about 0.0 M to about 0.3 M during a second time period following
the first time period.
4. The method of claim 2, wherein the concentration of the
dehydrating components in the second solution is increased from
about 0.0 M to about 0.3 M during a second time period following
the first time period.
5. The method of claim 1, further comprising the step of: prior to
delivering the first solution comprising a cryoprotectant into the
container, delivering a stabilizing solution into the container,
and thereafter delivering the first solution, during the first time
period, to gradually increase the concentration of cryoprotectant
in the container over the first time period.
6. The method of claim 1 wherein the cryoprotectant comprises DMSO,
ethylene glycol, propylene glycol, or glycerol, alone or in
combination.
7. The method of claim 1 wherein the dehydrating agent comprises
sucrose, dextrose, trehalose, lactose, or raffinose, alone or in
combination.
8. A method of preparing blastocysts for cryopreservation, said
method comprising: positioning one or more blastocysts in a
container; and flowing a first solution comprising a cryoprotectant
over the blastocysts by delivering the first solution into the
container and, for a first time period; after the first time
period, initiating removal of the first solution and flow of a
second solution comprising a dehydrating agent into the container;
wherein the step of initiating flow of the second solution is
initiated while some of the first solution is in the processing
container, and accomplished to continuously change the
concentration of the cryoprotectant and dehydrating agent in the
container.
9. The method of claim 8, wherein the concentration of the
cryoprotectant in the container is increased from about 0.0 M to
about 1.5 M during the first period.
10. The method of claim 8, wherein the concentration of the
dehydrating components in the container is increased from about 0.0
M to about 0.3 M during a second time period following the first
time period.
11. The method of claim 9, wherein the concentration of the
dehydrating components in the container is increased from about 0.0
M to about 0.3 M during a second time period following the first
time period.
12. The method of claim 7, further comprising the step of: prior to
delivering the first solution comprising a cryoprotectant into the
container, delivering a stabilizing solution into the container,
and thereafter delivering the first solution, during the first time
period, to gradually increase the concentration of cryoprotectant
in the container over the first time period.
13. The method of claim 12 wherein the cryoprotectant comprises
DMSO, ethylene glycol, propylene glycol, or glycerol, alone or in
combination.
14. The method of claim 7 wherein the dehydrating agent comprises
sucrose, dextrose, trehalose, lactose, or raffinose, alone or in
combination.
Description
[0001] This application is a divisional of U.S. application Ser.
No. 15/074,531, filed Mar. 18, 2016, pending, which is a divisional
of U.S. application Ser. No. 13/055,134, filed May 12, 2011,
pending, which is a national stage of PCT/US2009/051428 filed Jul.
22, 2009, which claims priority to U.S. Provisional Application
61/083,043, filed Jul. 23, 2008 and U.S. Provisional Application
61/116,255, filed Nov. 19, 2008. This application is also a
divisional of U.S. application Ser. No. 13/055,134, filed May 12,
2011, pending, which is a national stage of PCT/US2009/051428 filed
Jul. 22, 2009, which claims priority to U.S. Provisional
Application 61/083,043, filed Jul. 23, 2008 and U.S. Provisional
Application 61/116,255, filed Nov. 19, 2008.
FIELD OF THE INVENTION
[0002] The present invention relates generally to the field of
cryopreservation. In particular, the present invention relates to
systems and methods for providing automated change in the solution
environment for the cryopreservation and/or reanimation of oocytes,
embryos or blastocysts.
BACKGROUND OF THE INVENTION
[0003] This section is intended to provide a background or context
to the invention that is recited in the claims. The description
herein may include concepts that could be pursued, but are not
necessarily ones that have been previously conceived or pursued.
Therefore, unless otherwise indicated herein, what is described in
this section is not prior art to the description and claims in this
application and is not admitted to be prior art by inclusion in
this section.
[0004] The ability to cryopreserve and then reanimate oocytes,
embryos or blastocysts is desirable for many reasons. However,
conventional techniques have proven difficult to reproduce in an
effective, efficient and consistent manner. Such conventional
techniques are typically labor-intensive, requiring substantial
handling of the oocytes, embryos or blastocysts by a highly skilled
human technician. For example, conventional cryopreservation of an
oocyte requires that the technician manually move the oocytes from
one location to another in the cryopreservation process, such as
from incubation to washing solution to a cryoprotectant solution.
Further, oocytes frequently incur structural damage during
conventional cryopreservation techniques. For example, conventional
manual movement of oocytes among cryopreservation solution baths
can impart osmotic and thermal shock. For instance, formation of
ice crystals within the oocyte can cause intracellular damage in
the oocyte. Oocytes undergoing conventional cryopreservation
techniques can also experience a loss of sphericity and undesirable
changes in volume. Such effects may result in structural damage in
addition to toxicity, thereby significantly diminishing the
viability of the oocyte and ultimately reducing the probability of
successful fertilization.
[0005] Human involvement and conventional preservation techniques
greatly contribute to the lack of consistency in cryopreservation
of oocytes, embryos or blastocysts and results in an undesirably
low fertilization success rate. Therefore, it is desirable to
provide a partially automated method and system for the repeatable
and efficient cryopreservation and reanimation of oocytes, embryos
or blastocysts that mitigate effects harmful to the viability of
the oocyte, embryo or blastocyst, and thereby increasing the rate
of successful fertilization.
SUMMARY OF THE INVENTION
[0006] Various embodiments of the present invention provide a
method of cryopreservation and reanimation of oocytes, embryos or
blastocysts. The method comprises positioning one or more oocytes,
embryos or blastocysts in a processing container, the processing
container being configured to allow fluid to flow into and out of
the processing container; and flowing two or more fluids into and
out of the processing container with the oocytes, embryos or
blastocysts retained therein. In an embodiment, the method further
comprises controlling the temperature of the fluid in the
processing container according to predetermined requirements. The
flowing of the fluids may be controlled by a central controller
adapted to control one or more valves coupled to the processing
container.
[0007] Embodiments also provide for an apparatus for
cryopreservation and reanimation of oocytes, embryos or blastocysts
comprises a processing container configured to hold oocytes,
embryos or blastocysts therein, the processing container being
further configured to allow fluid to flow into and out of the
processing container; one or more reservoirs of fluids coupled to
the processing container; and a central controller adapted to
control the flow of fluids from the one or more reservoirs into the
processing container.
[0008] Various embodiments also provide for a reservoir configured
for dispensing fluid comprises a defined volume of fluid, the fluid
including one or more components for cryopreserving and reanimating
oocytes, embryos or blastocysts; a coupler configured to
fluidically couple the reservoir to an apparatus for
cryopreservation of oocytes, embryos or blastocysts; and electronic
identification indicia representative of an authorized reservoir,
wherein the electronic identification indicia is readable by the
cryopreservation apparatus.
[0009] In other embodiments, the invention relates to methods and
apparatus for the maturation of an egg in preparation for freezing
as well as development of an embryo after fertilization. The above
embodiments may be adapted to substantially simulate an in vivo
environment of the egg and/or the embryo. Solution fluids may be
directed into and out of the processing container containing one or
more of an egg and/or a fertilized embryo. Solution delivery may be
manipulated based on various parameters monitored over the
development and/or maturation period.
[0010] In yet another embodiment, the invention relates to a
central controller coupled to one or more valves configured to
control flow of fluids into and out of a processing container
configured to hold oocytes, embryos or blastocysts and coupled to a
thermal controller. The central controller may be configured to (a)
introduce an aqueous solution into the processing container
containing the oocytes, embryos or blastocysts, the aqueous
solution comprising a cryoprotectant maintained at a temperature of
from about 20.degree. to about 38.degree. C. to replace at least a
portion of intracytoplasmic water in the oocytes, embryos or
blastocysts by the cryoprotectant; (b) replace the aqueous solution
in the processing container with a first dehydrating/cryoprotecting
solution comprising a cryoprotectant and a dehydrating agent
maintained at a temperature of from about 20.degree. to about
38.degree. C. to remove additional intra-cytoplasmic water while
introducing additional cryoprotectant into the cytoplasm; and (c)
decrease the temperature of the dehydrating/cryoprotecting solution
to a temperature of from about 22.degree. to about 26.degree. C.
during a period of from about 3 to about 10 minutes.
[0011] Various embodiments of the present invention also relate to
a computer program product, embodied on a computer-readable storage
medium, for controlling one or more valves and/or pumps configured
to control flow of fluids into and out of a processing container
for oocytes, embryos or blastocysts and for controlling a thermal
controller. The computer program product comprises (a) computer
code for introducing an aqueous solution into the processing
container containing the oocytes, embryos or blastocysts, the
aqueous solution comprising a cryoprotectant maintained at a
temperature of from about 33.degree. to about 38.degree. C. to
replace at least a portion of intracytoplasmic water in the
oocytes, embryos or blastocysts by the cryoprotectant; (b) computer
code for replacing the aqueous solution in the processing container
with a first dehydrating/cryoprotecting solution comprising a
cryoprotectant and a dehydrating agent maintained at a temperature
of from about 33.degree. to about 38.degree. C. to remove
additional intra-cytoplasmic water while introducing additional
cryoprotectant into the cytoplasm; and (c) computer code for
decreasing the temperature of the dehydrating/cryoprotecting
solution to a temperature of from about 22.degree. to about
26.degree. C. during a period of from about 3 to about 10
minutes.
[0012] These and other advantages and features of the invention,
together with the organization and manner of operation thereof,
will become apparent from the following detailed description when
taken in conjunction with the accompanying drawings, wherein like
elements have like numerals throughout the several drawings
described below.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. 1 illustrates a cryopreservation and reanimation system
according to an embodiment of the present invention;
[0014] FIG. 2 illustrates the cryopreservation and reanimation
system of FIG. 1 with additional features;
[0015] FIG. 3A illustrates a cryopreservation and reanimation
system according to another embodiment of the present
invention;
[0016] FIG. 3B illustrates a cryopreservation and reanimation
system according to yet another embodiment of the present
invention;
[0017] FIG. 4A illustrates an embodiment of a reservoir for use
with the cryopreservation and reanimation systems illustrated in
FIGS. 1, 2, 3A, and 3B;
[0018] FIG. 4B illustrates another embodiment of a reservoir for
use with the cryopreservation and reanimation systems illustrated
in FIGS. 1, 2, 3A, and 3B;
[0019] FIG. 5 schematically illustrates a control arrangement for
use with the cryopreservation and reanimation system of FIGS. 1 and
2 in accordance with an embodiment of the present invention;
[0020] FIG. 6A illustrates an embodiment of an oocyte, embryo or
blastocyst basket for use with the cryopreservation and reanimation
systems of FIGS. 1, 2, 3A and 3B;
[0021] FIG. 6B illustrates another embodiment of an oocyte, embryo
or blastocyst container for use with the cryopreservation and
reanimation systems of FIGS. 1, 2, 3A and 3B;
[0022] FIG. 6C illustrates yet another embodiment of an oocyte,
embryo or blastocyst container for cryopreservation and reanimation
of oocytes, embryos or blastocysts for use with the
cryopreservation systems of FIGS. 1, 2, 3A and 3B;
[0023] FIG. 7 is a graphical representation of a solution
concentration profile for a cryopreservation system in accordance
with an embodiment of the present invention;
[0024] FIG. 8 is a graphical representation of another solution
concentration profile for a cryopreservation system in accordance
with an embodiment of the present invention;
[0025] FIG. 9 is a graphical representation of a solution
concentration profile for a reanimation system in accordance with
an embodiment of the present invention; and
[0026] FIG. 10 is a graphical representation of another solution
concentration profile for a reanimation system in accordance with
an embodiment of the present invention.
DETAILED DESCRIPTION OF VARIOUS EMBODIMENTS
[0027] As used herein, the following definitions shall apply unless
otherwise indicated.
[0028] The term "oocyte" refers to an unfertilized freshly
harvested or mature oocyte and refers to both the singular and
plural regardless of whether this term employs terms such as "a",
"the" and the like. The freshly harvested means that the oocytes
were harvested from the animal donor within 8 hours of initiation
of the stabilization/cryopreservation process, preferably within
about 4 hours of initiation of the stabilization/cryopreservation
process, more preferably within about 1 hour of initiation of the
stabilization/cryopreservation process, and even more preferably
within about 0.1 hour of initiation of the
stabilization/cryopreservation process The mature oocytes mean
harvested oocytes which are graded on a maturation scale as "mature
stage--MII." This scale further identifies harvested oocytes as
"intermediate stage--(MI)" or "immature stage--(GV)."
[0029] The term "reanimated oocytes" refers to thawed oocytes which
are capable of fertilization and embryo development.
[0030] The term "stabilized oocytes" refer to mature oocytes still
retaining the cumulus mass (granulosa cells) which permit
maturation of the oocyte by nutrient intake through gap junctions
in the cumulus mass. The mature oocyte is characterized by
formation of the meiotic spindle in conjunction with extrusion of
the first polar body while maintaining the integrity/activity of
the intracellular proteins.
[0031] The term "blastocyst" refers to a fertilized egg freshly
harvested from about 5 days after fertilization up to implantation
in the uterus and refers to both the singular and plural regardless
of whether this term employs terms such as "a", "the" and the like.
The term "freshly harvested" means that the blastocysts were
harvested from the animal donor within about 8 hours of initiation
of the stabilization/cryopreservation process, preferably within
about 4 hours of initiation of the stabilization/cryopreservation
process, more preferably within about 1 hour of initiation of the
stabilization/cryopreservation process, and even more preferably
within about 0.1 hour of initiation of the
stabilization/cryopreservation process.
[0032] The term "reanimated blastocyst" refers to thawed
blastocysts which are capable of embryo development.
[0033] The term "embryo" refers to a fertilized egg freshly
harvested from between the time of first division to two cells to
about 5 days after fertilization and refers to both the singular
and plural regardless of whether this term employs terms such as
"a", "the" and the like. The freshly harvested means that the
embryos were harvested from the animal donor within about 8 hours
of initiation of the stabilization/cryopreservation process,
preferably within about 4 hours of initiation of the
stabilization/cryopreservation process, more preferably within
about 1 hour of initiation of the stabilization/cryopreservation
process, and even more preferably within about 0.1 hour of
initiation of the stabilization/cryopreservation process.
[0034] The term "reanimated embryos" refers to thawed embryos which
are capable of further embryonic and fetal development.
[0035] In the following description, for purposes of explanation
and not limitation, details and descriptions are set forth in order
to provide a thorough understanding of the present invention.
However, it will be apparent to those skilled in the art that the
present invention can be practiced in other embodiments that depart
from these details and descriptions.
[0036] Various processes for cryopreservation and reanimation of
oocytes are conventionally known. One such process for
cryopreserving freshly harvested mature animal oocytes comprises:
incubating freshly harvested mature oocytes in one or more
stabilization solutions maintained at a temperature of from about
33.degree. to about 38.degree. C. for a period of time sufficient
to stabilize the oocytes to in vitro conditions, wherein when more
than one stabilization solution is employed, each solution is
different from each other. The stabilization solutions include, but
are not limited to, those solutions wherein the freshly harvested
mature oocyte is incubated after in vivo extraction and which
permit the oocytes to equilibrate in its in vitro environment prior
to initiation of the cryopreservation process. The stabilization
solutions are intended to permit further maturation of the oocytes
in vitro. Specifically, the stabilization solutions are designed to
mimic the environment within the follicle from which the eggs were
removed. The follicle supports ongoing processes of the oocyte
maturation in vivo which are preferably duplicated when the oocytes
are removed from the follicle and placed into the stabilization
solution. The stabilization solution also provides nutrients for
further meiotic development and supports metabolic processes
continuing within the oocyte as well as supports the cell membrane.
A further function of the stabilization solution is to remove
biological wastes occurring from metabolism within the oocytes and
to stabilize the intra-oocyte pH. The stabilization solution does
not include any cryoprotectant, e.g., dimethyl sulfoxide (DMSO),
propylene glycol, or the like.
[0037] Stabilization solutions include, by way of the example,
Global.RTM. media (available from Life Global, IVF Online),
Global.RTM. media supplemented with SSS (available from Irvine
Scientific, Santa Ana, Calif., USA), human tubal solution
(HTF--available from Irvine Scientific, Santa Ana, Calif., USA)
optionally supplemented with SSS and/or an antibiotic (e.g.,
gentamicin) and modified HTF (HTF with HEPES (mHTF)--available from
Life Global, IVF Online) optionally supplemented with SSS and/or an
antibiotic (e.g., gentamicin), phosphate buffered saline (PBS),
sodium depleted PBS (e.g., sodium hydrogen phosphate (H2NaPO4)) and
the like.
[0038] Cryoprotectant is introduced into the stabilized mature
oocyte by contacting the oocyte with an aqueous solution comprising
a cryoprotectant maintained at a temperature of from about
33.degree. to about 38.degree. C. under conditions wherein at least
a portion of the intracytoplasmic water is replaced by
cryoprotectant. The cryoprotectant include, but are not limited to,
a liquid which permeates across the cell wall of the animal oocyte
typically by osmotic methods and which promotes survival and
retention of viability of the oocyte during the process of
cryopreserving as well as in the cryopreserved state. Suitable
cryoprotectants are well known in the art and include, by way of
example only, DMSO, ethylene glycol, propylene glycol
(1,2-propanediol), glycerol, as well as mixtures of 2 or more of
such cryoprotectants, and the like.
[0039] The oocyte is then transferred to at least a first
dehydrating/cryoprotecting solution comprising a cryoprotectant and
a dehydrating agent maintained at a temperature of from about
33.degree. to about 38.degree. C. under conditions sufficient to
remove additional intra-cytoplasmic water while introducing
additional cryoprotectant into the cytoplasm The temperature of the
dehydrating/cryoprotecting solution is then decreased to about
22.degree. to about 26.degree. C. during a period of from about 3
to 10 minutes, and the oocyte is then transferred in the
dehydrating/protecting solution into a container which is then
sealed, and the oocytes are then cryopreserved. The
dehydrating/cryoprotecting solution include, but are not limited
to, a cryoprotecting solution as described above which further
comprises an agent to facilitate dehydration of the
intra-cytoplasmic water in the oocyte during cryopreservation
Preferably, such agents do not osmotically traverse the cellular
wall of the oocyte Dehydrating agents include, sucrose, dextrose,
trehalose, lactose, raffinose, and the like.
[0040] Embodiments of the present invention provide systems and
methods which allow for the automation of one or more of the steps
of cryopreservation and reanimation techniques for oocytes, such as
described above. Embodiments of the present invention are also
adaptable for cryopreservation and reanimation of embryos and
blastocysts. Embodiments of the present invention are particularly
well suited for cryopreservation and reanimation of human oocytes,
embryos, and blastocysts. The various exemplary embodiments will be
described as and referred to as cryopreservation systems. However,
it should be understood that the embodiments are not limited to
cryopreservation but are also adapted for reanimation of oocytes,
embryos and blastocysts. Additionally, the various embodiments may
also be adapted for maturation of an egg in preparation for
freezing as well as development of an embryo after
fertilization.
[0041] Referring to FIG. 1, a cryopreservation system according to
an embodiment of the present invention is illustrated. The
cryopreservation system 100 includes an incubator 110 for
incubation of freshly harvested mature oocytes, embryos or
blastocysts 10. As noted above, the oocytes, embryos or blastocysts
10 may be incubated in one or more stabilization solutions
maintained at a temperature of from about 33.degree. to about
38.degree. C. for a period of time sufficient to stabilize the
oocytes, embryos or blastocysts 10 to in vitro conditions. Once the
incubated oocytes, embryos or blastocysts 10 are stabilized, they
are transported to a processing container 120.
[0042] The processing container 120 can be formed of a variety of
materials, such as metals or plastics, for example. The processing
container may be configured for efficient disassembly from the
cryopreservation system 100 for sterilization. Alternatively, the
processing container may be configured for single-use. The
processing container 120 may be sized for specific uses and needs.
In an embodiment, the processing container 120 has an internal
volume 122 of about 0.0004 to about 0.02 ml. In another embodiment,
the internal volume 122 is about 0.004 to about 0.008 ml. The
internal volume 122 is configured to accommodate one or more
oocytes, embryos or blastocysts 10 therein, along with a fluid
solution. The oocytes, embryos or blastocysts 10 may be protected
from other components of the processing container by a barrier. For
example, the oocytes, embryos or blastocysts 10 can be separated
from an inlet 130 and an outlet 140 of the processing container by
a membrane 125 or another form of a barrier, generically
illustrated in FIG. 1 by a dashed line. The membrane 125 is
configured to retain the oocytes, embryos or blastocysts 10 within
the processing container during processing, yet permit flow through
of the processing solutions to allow for bathing of the oocytes,
embryos or blastocysts 10. In an embodiment, the membrane 125
comprises a porous substrate with pores of about 5 .mu.m to about
70 .mu.m in diameter.
[0043] In another embodiment, the oocytes, embryos or blastocysts
10 are retained in a basket 600 configured to fit within the
processing container 120, as depicted in FIG. 6A. The basket
includes a plurality of pores 610 configured for flow through of
the processing solutions but not greater than about 50 .mu.m in
diameter for retention of the oocytes, embryos or blastocysts 10
within the basket.
[0044] In yet another embodiment, depicted in FIG. 6B, the oocytes,
embryos or blastocysts 10 are loaded into a processing container
650 that is capable of being substantially sealed. The processing
container 650 is configured with an inlet 660 and one or more
outlets 670. The inlet 660 is configured for inflow of the
processing solutions and the one or more outlets 670 are configured
for outflow of the processing solutions. The inlet 660 and the one
or more outlets 670 are further configured to retain the oocytes,
embryos or blastocysts 10 within the processing container 650
during processing. In one configuration, the inlet 660 and the one
or more outlets 670 are not greater than about 100 .mu.m in
diameter.
[0045] In still another embodiment, depicted in FIG. 6C, the
oocytes, embryos or blastocysts 10 enter a track 680. The track 680
comprises a hollow tube 681 forming a loop and configured with one
or more ports. The loop formed by the hollow tube 681 is
substantially circular in an embodiment and has a diameter of at
least about 1 inch. The hollow tube 681 is sized to accommodate at
least the normal maximum diameter of an oocyte, embryo or
blastocyst 10 and a boundary layer of solution sufficient for
cryopreservation of the oocyte, embryo or blastocyst 10. In an
embodiment, the inner diameter of the hollow tube 681 is at least
about 0.03 inch.
[0046] The oocytes, embryos or blastocysts 10 enter the track 680
from a port 682. In an embodiment, the track 680 is configured for
clockwise flow of the solution fluids and the oocytes, embryos or
blastocysts 10 about the loop formed by the hollow tube 681. The
port 682 is disposed on the track 680 such that the oocytes,
embryos or blastocysts 10 are substantially prevented from exiting
through the port 682 while clockwise fluid flow is maintained
within the hollow tube 681. The solution fluids enter the track 680
through a solution port 684. The solution port 684 is disposed on
the track 680 to encourage clockwise flow about the track 680 in
response to entry of the solutions into the hollow tube 681. The
solution port 684 is similarly disposed on the track 680 to prevent
entry of the oocytes, embryos or blastocysts 10. The solution port
684 is coupled to a plurality of reservoirs 150, 160, 170, and 180
or a single reservoir 300/301, illustrated in FIGS. 2 and 4A/4B
respectively. Excess solution escapes from the track 680 through a
plurality of slits 688 disposed on the outer surface of the hollow
tube 681 and substantially normal to the flow direction within the
track 680. The slits 688 are configured to prevent escape or
capture of the oocytes, embryos or blastocysts 10 within the hollow
tube 681. In an embodiment, the slits 688 are not greater than
about 50 .mu.m in width. The track 680 optionally includes a gas
port 686 disposed substantially opposite the port 682. The track
680 may further include a temperature controller 689 for control of
the process temperature.
[0047] The oocytes, embryos or blastocysts 10 are carried around
the loop formed by the hollow tube 681 by a substantially
continuous flow of cryoprotectant solutions until the
cryopreservation process is complete. Upon process completion,
suction is provided at the port 682 to retrieve the oocytes,
embryos or blastocysts 10 from the track 680. The gas port 686
supplies a positive pressure to facilitate retrieval of the
oocytes, embryos or blastocysts 10 from the track 680 through the
port 682.
[0048] As illustrated in FIG. 1, the processing container 120 is
configured to allow fluid to flow into and out of the internal
volume 122. In the illustrated embodiment the flow of fluid into
and out of the internal volume 122 is controlled by valves in the
inlet 130 and the outlet 140, such as an inlet valve 132 and an
outlet valve 142. The inlet valve 132 and outlet valve 142 are
sized to accommodate the flow of fluid as required for the
processing of the oocytes, embryos or blastocysts 10. The
processing container 120 optionally includes a baffle 126 to
improve solution mixing within the processing container.
[0049] The processing container 120 is also provided with a thermal
controller 124 configured to control the temperature of the fluid
in the internal volume 122. Various configurations may be used to
control fluid temperature. For example, the solutions may be held
at room temperature, and at least a portion of the solution is
heated and cooled, as necessary, to achieve the desired process
solution temperature. In an embodiment, the process temperature
range is from about 20.degree. to about 37.degree. C.
Alternatively, the solutions may be maintained at about the maximum
of the process temperature range, and at least a portion of the
solution is cooled, as necessary, to achieve the desired process
solution temperature. In yet another embodiment, the solutions may
be maintained at about the minimum of the process temperature
range, and at least a portion of the solution is heated, as
necessary, to achieve the desired process solution temperature. In
the embodiment illustrated in FIGS. 1 and 2, the thermal controller
124 is coupled to a wall of the processing container 120. In other
embodiments, a thermal controller 124 may be coupled to the inlet
130 to control the temperature of the fluid entering the internal
volume 122 of the processing container 120. In still other
embodiments, one or more of the thermal controllers 124 may couple
to the plurality of reservoirs 150, 160, 170, and 180. Still
further, the thermal controller 124 may be implemented in any of
numerous other manners known in the art to allow thermal control of
the fluid in the internal volume 122.
[0050] The cryopreservation system may include one or more solution
reservoirs fluidically coupled to the processing container 120.
Referring to FIG. 2, the cryopreservation system of FIG. 1 is
illustrated with additional features. In the illustrated
embodiment, the cryopreservation system includes the plurality of
reservoirs 150, 160, 170, and 180 fluidically coupled to the
processing container 120. The plurality of reservoirs 150, 160,
170, and 180 hold one or more solutions appropriate for the
cryopreservation or reanimation of the oocytes, embryos or
blastocysts 10 within the processing container 120. In the
illustrated embodiment, the reservoir 150 holds a volume of
solution I; the reservoir 160 holds a volume of solution II; the
reservoir 170 holds a volume of solution III; and the reservoir 180
holds a volume of solution IV. The plurality of reservoirs 150,
160, 170, and 180 are configured to hold a volume of solution
sufficient to process one or more batches of oocytes, embryos or
blastocysts 10 within the processing container 120. In an
embodiment, the plurality of reservoirs 150, 160, 170, and 180 have
a substantially equal volume of about 3 ml. In another embodiment,
the plurality of reservoirs 150, 160, 170, and 180 are of various
volumes, sized in relation to the volume of their respective
solutions for processing the oocytes, embryos or blastocysts
10.
[0051] The composition of the solutions I, II, III, and IV is
configured to provide the desired sequence of solutions for
cryopreservation or reanimation of the oocytes, embryos or
blastocysts 10 according to, for example, the cryopreservation
process described above. In this regard, in an embodiment, Solution
I includes an aqueous stabilizing solution comprising a modified
human tubal fluid ("mHTF") and a synthetic serum substitutes
("SSS") as known in the art. Solution II comprises an aqueous
solution of mHTF, SSS, and a cryoprotectant configured to replace
at least a portion of the intracytoplasmic water in the oocytes,
embryos or blastocysts 10 with cryoprotectant. Solution III
comprises a first dehydrating/cryoprotecting solution including a
cryoprotectant and a dehydrating agent configured to remove
additional intra-cytoplasmic water from the oocytes, embryos or
blastocysts 10 while introducing additional cryoprotectant into the
cytoplasm. Solution IV comprises a second
dehydrating/cryoprotecting solution including a cryoprotectant and
a dehydrating agent configured to remove additional
intra-cytoplasmic water from the oocytes, embryos or blastocysts 10
while introducing additional cryoprotectant into the cytoplasm. The
system is readily adapted for use with alternative solutions or
solution components. For example, in an embodiment, SSS is
eliminated from the solutions. In another embodiment, solutions
comprising saline, HTF, mHTF, and an aqueous solution including
choline chloride may be used. In addition, other solutions and
solution components may be used with the various embodiments to
achieve the desired cryopreservation or reanimation of oocytes,
embryos, and/or blastocysts.
[0052] In another embodiment, each of the plurality of reservoirs
may contain one or more of the solution components of the solutions
I, II, III, and IV. For example, the embodiment of FIG. 2
illustrates the plurality of reservoirs 150, 160, 170, and 180. In
this embodiment, each of the four reservoirs contains a volume of
an individual solution component or mixture of selected solution
components at an appropriate concentration corresponding to the
process described above or other cryopreservation process. For
example in an embodiment, the reservoir 150 includes a volume of
mHTF; the reservoir 160 includes a volume of SSS; the reservoir 170
includes a volume of cryoprotectant; and the reservoir 180 includes
a volume of dehydrating solution. Combinations of the components
with each other or other components may be included in the
plurality of reservoirs 150, 160, 170, and 180. Again, the system
is readily adapted for use with alternative solutions or solution
components as earlier described. An appropriate volume of the
solution components from the plurality of reservoirs 150, 160, 170,
and 180 are released through the plurality of corresponding valves
152, 162, 172 and 182. The solution components mix to form the
solutions I, II, III, and IV, or other combinations thereof,
corresponding to the different stages of the cryopreservation
process. The manifold 190 is configured to enhance the mixing of
the solution components to form adequately homogenous solutions
prior to release of the solutions into the processing container
120.
[0053] The plurality of reservoirs 150, 160, 170, and 180 are
fluidically coupled to the manifold 190 with a plurality of
corresponding couplers 156, 166, 176, and 186. The plurality of
corresponding couplers 156, 166, 176, and 186 are configured to
couple to a plurality of corresponding manifold connections 195,
196, 197, and 198. The corresponding plurality of couplers 156,
166, 176, and 186 may be uniquely configured to couple to only one
of the plurality of corresponding manifold connections 195, 196,
197, and 198. The unique connections may be accomplished through
any one of a number of techniques known in the art, such as, but
not limited to, connection diameter, internal and/or external
engagement features, connection thread pitch, connection thread
direction, keyed connectors, or any combination thereof. Unique
coupling connections ensure correct assembly of the plurality of
reservoirs 150, 160, 170, and 180 to the manifold 190 and delivery
of the appropriate solutions to the processing container 120.
[0054] In an embodiment, each of the plurality of reservoirs 150,
160, 170, and 180 comprise a reservoir surface forming a
substantially closed vessel. The reservoir surface may be of a
rigid, semi-rigid, or deformable material that is non-reactive with
the solutions or solution components retained therein. The
reservoir surface may be formed into a generally cylindrical shape
or another form suitable for storing and dispensing the solutions.
The reservoir surface includes at least one opening whereby the
solution or solution component exits the respective reservoir
through the corresponding plurality of couplers 156, 166, 176, and
186. The reservoir surface may be constructed with an integral
opening or the opening may be formed when the respective reservoir
is coupled to the cryopreservation system 100. In an embodiment,
the opening and/or reservoir surface may form all of or a portion
of the corresponding valves 152, 162, 172 and 182.
[0055] In an embodiment, the plurality of reservoirs 150, 160, 170,
and 180 are configured for limited use. For example, limited
volumes of the solutions or solution components may be provided
sufficient only to process a predefined number of oocyte, embryo or
blastocyst batches. In an embodiment, the volumes of solutions or
solution components are configured for processing a single batch of
oocytes, embryos or blastocysts Once a single-use reservoir is
depleted, the reservoir is decoupled from the cryopreservation
system 100 and a replacement reservoir, filled with the appropriate
solution or solution component, is attached. Alternatively, the
plurality of reservoirs 150, 160, 170, and 180 may be configured
for limited use based on other parameters.
[0056] For instance, to ensure optimal performance, the plurality
of reservoirs 150, 160, 170, and 180 may be configured with
electronic data indicative of a date, an age, or an expiration date
of the solution or solution component readable by the
cryopreservation system 100. The cryopreservation system 100 may
deny use if it detects an expired reservoir in certain embodiments.
Similarly, the plurality of reservoirs 150, 160, 170, and 180 may
be configured with electronic identification data indicative of the
solution or the solution component readable by the cryopreservation
system 100. The cryopreservation system 100 may deny use in various
embodiments if it detects a reservoir containing an improper or
incompatible solution or solution component.
[0057] The electronic data and electronic identification data may
be associated with or stored on the plurality of reservoirs 150,
160, 170, and 180 in a reservoir storage structure using any of the
variety of storage structures known in the art. For instance, an
EPROM, non-volatile memory, magnetic strip, RFID, or other storage
structure can be associated with each of the plurality of
reservoirs the 150, 160, 170, and 180 to store the data. In
embodiments where two or more reservoirs are coupled, a portion of
the reservoir storage structure may be associated with each of the
reservoirs. The cryopreservation system 100 is provided with a
corresponding system to detect and read the data from the reservoir
storage structures. The cryopreservation system 100 reads the data
from the reservoir storage structure and compares the data to
existing or downloaded data within the cryopreservation system 100
or external data.
[0058] In an embodiment, the electronic identification indicia may
be used to ensure that the plurality of reservoirs 150, 160, 170,
and 180 are coupled to the proper plurality of corresponding
manifold connections 195, 196, 197, and 198. The cryopreservation
system 100 may deny use if it detects an improperly coupled
reservoir or a reservoir that is coupled an incorrect one of the
plurality of corresponding manifold connections 195, 196, 197, and
198. In another embodiment, the cryopreservation system 100 is
dynamically adaptable such that the configuration of the plurality
of reservoirs 150, 160, 170, and 180 to the of corresponding
manifold connections 195, 196, 197, and 198 is irrelevant. The
cryopreservation system 100 detects the electronic identification
indicia of the plurality of reservoirs 150, 160, 170, and 180 and
configures operation accordingly. In this particular embodiment, it
is unnecessary to provide unique coupling configurations for the
plurality of corresponding manifold connections 195, 196, 197, and
198 and the corresponding plurality of couplers 156, 166, 176, and
186.
[0059] In another embodiment, to prevent use of uncertified
solutions or counterfeit solutions, the plurality of reservoirs
150, 160, 170, and 180 may include electronic identification
indicia readable by the cryopreservation system 100 and indicative
of an authorized reservoir. The cryopreservation system 100 may
deny use if it is unable to verify the integrity of the reservoir,
the solution, or solution component via the electronic
identification indicia or other indicia. The electronic
identification indicia or other indicia may be encoded or encrypted
to prevent unauthorized replication of the indicia. The
cryopreservation system 100 may deny operation if it fails to
detect an authorized reservoir among the plurality of reservoirs
150, 160, 170, and 180 based on the electronic identification
supplied by the reservoir. The electronic identification indicia
may further be configured to lapse upon depletion of a reservoir.
Still further, the electronic identification indicia of the
plurality of reservoirs 150, 160, 170, and 180 may be automatically
or manually associated with one or more particular batches of
oocytes, embryos or blastocysts processed in the cryopreservation
system 100 and stored in a data record for subsequent recall or
analysis. The plurality of reservoirs 150, 160, 170, and 180 may be
disposable following use or may be configured for authorized reuse
If the reservoir is reusable, upon depletion, the reservoir is
returned to a solution provider for authorized replenishment of
solution and renewal of the electronic identification indicia.
[0060] The contents of the plurality of reservoirs 150, 160, 170,
and 180 are directed to the internal volume 122 of the processing
container 120 through a manifold 190. The flow of the solutions I,
II, III, and IV or solution components to the internal volume 122
may be controlled through one or more valves. As illustrated in the
embodiment of FIG. 2, delivery of the solution or solution
component from the plurality of reservoirs 150, 160, 170, and 180
may be regulated through a plurality of corresponding valves 152,
162, 172, and 182, respectively. An inlet valve 132, downstream of
the corresponding valves 152, 162, 172, and 182 may further be
provided to control flow into the processing container 120. The
plurality of corresponding valves 152, 162, 172, and 182 may
comprise one or more of any of several manual or automatic valve
types or structures known in the art capable of restricting fluid
flow. In the illustrated embodiment, the corresponding valves 152,
162, 172, and 182 are positioned between the corresponding manifold
connections 195, 196, 197, and 198 and the processing container
120. In another embodiment, the corresponding valves 152, 162, 172,
and 182 are positioned between the plurality of reservoirs 150,
160, 170, and 180 and the corresponding couplers 156, 166, 176, and
186. In yet another embodiment, a portion of the reservoir surface
comprises the corresponding valves 152, 162, 172, and 182.
[0061] The solutions or solution components are delivered from
their respective reservoirs to the processing container 120 by one
or more fluid delivery techniques known in the art. For example,
the cryopreservation system 100 may be configured for gravity feed
of the solutions into the processing container 120. In another
embodiment, a pump 135 may be installed between the plurality of
reservoirs 150, 160, 170, and 180 and the processing container 120
for delivery of the solutions to the processing container 120.
Alternatively, or in addition to the pump 135, a pump may be
associated with each of the plurality of reservoirs 150, 160, 170,
and 180 to deliver the respective solutions to the manifold
190.
[0062] In another embodiment, air and/or inert gas is used alone,
or in combination with one or more pumps, to dispense the solutions
to the processing container 120. For example, the plurality of
reservoirs 150, 160, 170, and 180 may be configured to include a
corresponding gas inlet 154, 164, 174, and 184. The
cryopreservation system 100 supplies pressurized gas to the
plurality of reservoirs 150, 160, 170, and 180 via gas lines
coupled to the respective corresponding gas inlets 154, 164, 174,
and 184. Supply of the individual solutions or solution components
to the processing container 120 is regulated by the gas flow to
each of the plurality of reservoirs 150, 160, 170, and 180. In this
configuration, the plurality of corresponding valves 152, 162, 172,
and 182 need only be responsive to pressure changes within the
plurality of reservoirs 150, 160, 170, and 180 supplied by the gas.
Each of the corresponding gas inlets 154, 164, 174, and 184 may be
uniquely configured such that only a specific gas line,
corresponding to one of the plurality of reservoirs 150, 160, 170,
and 180, may be coupled. Provision of unique configurations
eliminates human error when installing new reservoirs. The
regulation of gas flow may be fully automated based on a defined
cryopreservation process sequence or in response to
cryopreservation process parameters monitored during the course of
the process. Use of an inert gas to deliver the solutions has the
added benefit, in an at least partially closed cryopreservation
system, of regulating the cryopreservation process pressure, which
may advantageously improve inflow of cryoprotectants across the
oocyte, embryo or blastocyst cell boundary. Further, conducting the
cryopreservation process an inert atmosphere reduces the
opportunity for contaminants to enter the cryopreservation system
100.
[0063] Other configurations of the solution reservoirs of the
cryopreservation system 100 can also be constructed. Referring to
FIGS. 4A and 4B, embodiments of single reservoir systems are
depicted. In the illustrated embodiments, a single reservoir
containing each of the solutions or solution components is coupled
to the processing container 120. In these embodiments, individual
solutions or solution components are maintained in sub-compartments
within the single reservoir.
[0064] In the embodiment depicted in FIG. 4A, a single reservoir
300 houses a plurality of sub-compartments 310, 320, 330, and 340.
Each of the plurality of sub-compartments 310, 320, 330, and 340
hold a volume of solution or solution component for use in the
cryopreservation of the oocytes, embryos or blastocysts 10 within
the processing container 120. The single reservoir 301 includes a
reservoir coupler 316 configured to couple to an inlet connection
318 of the cryopreservation system 100. A reservoir manifold 305
fluidically interconnects the plurality of sub-compartments 310,
320, 330, and 340 with the reservoir coupler 316. The reservoir
manifold 305 may include a plurality of corresponding valves 311,
321, 331, and 341 associated with the plurality of the
sub-compartments 310, 320, 330, and 340. The plurality of
corresponding valves 311, 321, 331, and 341 may be selected from
any of a number of valve types known in the art for controlling or
restricting flow. The illustrated embodiment may be configured for
use with the process solutions or the solution components.
[0065] In the embodiment depicted in FIG. 4B, a single reservoir
301 houses a plurality of interconnected sub-compartments 350, 360,
370, and 380. Each of the plurality of sub-compartments 350, 360,
370, and 380 hold a volume of solution for the cryopreservation of
the oocytes, embryos or blastocysts 10 within the processing
container 120. The single reservoir 301 includes a reservoir
coupler 316 configured to couple to an inlet connection 318 of the
cryopreservation system 100. A plurality of corresponding valves
351, 361, 371, and 381 control fluid flow out of the plurality of
sub-compartments 350, 360, 370, and 380. The plurality of
corresponding valves 351, 361, 371, and 381 can be selected from
any of a number of valve types known in the art for restricting
flow. The illustrated embodiment is primarily configured for use
with ordered process solutions. For example, the sub-compartment
350 contains a volume of solution I; the sub-compartment 360
contains a volume of solution II; the sub-compartment 370 contains
a volume of solution III; and the sub-compartment 380 contains a
volume of solution IV. In this manner, the single reservoir 301 is
generally applicable for single-use, wherein a single oocyte,
embryo or blastocyst batch may be processed with the single
reservoir 301. A new single reservoir 301 is coupled to the
cryopreservation system 100 to process each subsequent oocyte,
embryo or blastocyst batch.
[0066] The solutions or solution components are delivered from the
single reservoirs 300/301 to the processing container 120 by one or
more fluid delivery techniques known in the art. For example, the
cryopreservation system may be configured for gravity feed of the
solutions into the processing container 120. Additionally, a pump
135 may be installed between the single reservoirs 300/301 and the
processing container 120 for delivery of the solutions to the
processing container 120.
[0067] Still further, air and/or inert gas may be used alone, or in
combination with one or more pumps, to dispense the solutions to
the processing container 120. For example, gas may be supplied to
each the plurality of sub-compartments 310, 320, 330, and 340
through gas inlet 302. In an embodiment, the gas inlet 302 is
configured to provide individually controllable gas streams to each
of the plurality of sub-compartments 310, 320, 330, and 340. The
gas streams are regulated by the cryopreservation system 100 in
response to a defined process and/or monitored preservation process
parameters. In this configuration, the plurality of corresponding
valves 311, 321, 331, and 341 need only be responsive to pressure
changes within the plurality of sub-compartments 310, 320, 330, and
340 supplied via the gas inlet 302. This configuration may also be
adapted for use with the single reservoir 301.
[0068] In another embodiment, the gas inlet 302 is configured to
provide a single regulated gas stream to all of the
sub-compartments. In this configuration, the plurality of
corresponding valves 351, 361, 371, and 381 may be configured to be
progressively responsive to increasing gas flow received by the
plurality of sub-compartments 350, 360, 370, and 380 from the gas
inlet 302. For example, the valve 381 is responsive to a pressure
P.sub.1 supplied to the plurality of sub-compartments 350, 360,
370, and 380 such that a volume of solution I contained in
sub-compartment 380 is released to the inlet 130. The valve 371 is
responsive to a pressure P.sub.2, which is greater than P.sub.1
thereby releasing a volume of solution II. The valve 361 is
responsive to a pressure P.sub.3, which is greater than P.sub.2,
thereby releasing a volume of solution III. The valve 351 is
responsive to a pressure P.sub.4, which is greater than P.sub.3,
thereby releasing a volume of solution IV Regulation of gas flow
may be fully automated based on a defined cryopreservation process
sequence or in response to cryopreservation process parameters
monitored during the course of the process.
[0069] The single reservoir 300/301 provides a convenient
configuration for replenishment of the cryoprotectant solutions of
the cryopreservation system 100 and minimizes the opportunity of
error during replenishment. Further, the single reservoir 300/301
may be configured for single use or a limited number of uses such
as by providing volumes of solutions or solution components
sufficient only for the preservation of one, or a predefined
number, of oocyte, embryo or blastocyst batches. Further, the
single reservoir 300/301 may include electronic identification
indicia readable by the cryopreservation system 100 and indicative
of an authorized reservoir. The electronic identification indicia
may be configured to lapse upon depletion of the single reservoir
300/301. The cryopreservation system 100 may deny use of the
reservoir 300/301 if it fails to detect a signal indicative of an
authorized reservoir. Still further, the electronic identification
indicia of the single reservoir 300/301 may be automatically or
manually associated with a particular batch of processed oocytes,
embryos or blastocysts and stored in a data record for subsequent
recall or analysis. The single reservoir 300/301 may also be
configured for authorized reuse. Upon depletion of the single
reservoir 300/301, it is returned to a solution provider for
authorized replenishment with cryoprotectant and renewal of the
electronic identification indicia.
[0070] In the above embodiments, systems have been described having
a plurality of reservoirs or sub-compartments comprising four
reservoirs or sub-compartments. However, other embodiments having
either greater or fewer reservoirs or sub-compartments may be
constructed. For example, one or more of the solutions or the
solution components may be combined in one or more of the plurality
of reservoirs or in one or more of the plurality of
sub-compartments. Combining the solutions or solution components
thereby reduces the total number of reservoirs coupled to the
processing container 120 or reducing the total number of
sub-compartments within the single reservoir 300/301. Still other
embodiments can be constructed for use with cryopreservation
processes employing additional solutions or solution components
where more than four reservoirs or sub-compartments are desired.
Other solution components may include permeation enhancers
configured to enhance the outflow of aqueous components out of
and/or the inflow of cryoprotectants into the oocyte, embryo or
blastocyst.
[0071] In the above described embodiments, continuous temperature
control may be provided during the cryopreservation or reanimation
process to mitigate thermal shock and prevent formation of
intracellular ice crystal in the oocytes, embryos or blastocysts
10. The thermal controller 124 adjusts the temperature of the
solution as it enters or after it has entered the internal volume
122. In another embodiment, the temperature of the solutions or
solution components within the plurality of the reservoirs 150,
160, 170, and 180 is at least partly controlled within the
reservoirs by thermal controllers 124 so that when the solution
enters the internal volume 122 of the processing container 120, the
solution temperature is not significantly different from the
desired temperature for the cryopreservation or reanimation
process. In another embodiment, the desired temperature of the
various solutions is at least partially attained by a temperature
controller 124 coupled to the manifold 190. In yet another
embodiment, a combination thermal controller is implemented whereby
multiple thermal controllers are used. For example, the thermal
controller 124 maintains the solution temperature in the solution
reservoirs within a desired range and, more precisely, regulates
the temperature of the solution in the processing container 120.
Continuous temperature control of the processing solutions reduces
thermal stress imparted to the oocyte, embryo or blastocyst while
in the cryopreservation system 100 and improves viability of the
processed oocytes, embryos or blastocysts.
[0072] The above described embodiments of the cryopreservation
system may also be adapted for use in various other contexts by
using alternative solutions and/or solution components. For
example, the above described embodiments may be used for maturation
of an egg in preparation for freezing as well as development of an
embryo after fertilization. The cryopreservation system may be
adapted for processing of a single embryo or egg or configured to
simultaneously process a plurality of embryos and or eggs in a
single or multiple processing containers. For example, multiple
processing containers may be coupled to a manifold to deliver
solutions and/or solution components. In one such embodiment,
solutions and/or solution components may be used to substantially
simulate an in vivo environment of the egg and/or the embryo, e.g.
traversal of a fallopian tube. Further, solution control may also
be adapted to substantially simulate the in vivo environment.
Solution fluids may be directed into and out of the processing
container containing one or more of an egg and/or a fertilized
embryo.
[0073] In one embodiment, the solution fluids are delivered to the
processing container to substantially simulate a relative velocity
of the one or more eggs and/or fertilized embryos from about 2
cm/day to about 1 cm/hour. In yet another embodiment, delivery of
the solution fluids to the processing container may be controlled
at least in part on the concentration of dissolved oxygen of the
solution environment. In still another embodiment, delivery of
solution fluids, including change, addition, and deletion of
solutions or solution components, to the process container may be
controlled over the course of the maturation and/or development
period.
[0074] In yet another embodiment, imaging and or detection
capability may be used to visualize and monitor the viability of
the one or more eggs and/or embryos over the course of the process.
Various imaging techniques and measurement systems known in the
art, such as ultrasound and optical imaging systems, may be used to
assess integrity, growth and well being of the one or more eggs
and/or embryos. The collected information may also be used to
control and/or modify solution delivery to the processing
container.
[0075] Referring to FIG. 5, a control arrangement for use with the
cryopreservation system of FIGS. 1, 2, 3 A and 3B is schematically
illustrated. The control arrangement comprises a central controller
199 coupled to various components of the cryopreservation system.
The central controller 199 may be implemented as a central
processing unit (CPU) or other such device. In an embodiment, the
central controller 199 includes a processor and a memory unit. The
memory unit includes computer code for executing the various steps
of a method to effect the cryopreservation of the oocytes, embryos
or blastocysts.
[0076] As schematically illustrated in FIG. 5, the central
controller 199 is coupled to various components of the
cryopreservation system, such as the inlet valve 132, the outlet
valve 142 and the plurality of corresponding valves 152, 162, 172,
182 associated with each of the solution reservoirs of FIG. 2. The
central controller 199 is also coupled to the temperature
controller 124. Thus, the central controller 199 is able to control
operation of the cryopreservation system by controlling the
contents and conditions of the internal volume 122 of the
processing container 120 in which the oocytes, embryos or
blastocysts 10 are located.
[0077] The central controller 199 may be adapted to execute
computer code for automatically performing a method to effect a
cryopreservation or reanimation process by, for example, opening
and closing the various valves and controlling the thermal control
unit. Further, the central controller 199 may be configured to
receive signals from one or more sensors 198 which may be
positioned in or on the processing container 120 and in or on the
various other structures comprising the cryopreservation system
100. The sensors 198 provide the central controller 199 with such
information as the temperature, pressure, pH, and composition of
the fluid in the internal volume 122 of the processing container
120. The sensors 198 may also provide the central controller 199
with the temperature of solution within the inlet 130, the outlet
140, and the plurality of reservoirs 150, 160, 170, and 180. The
sensors 198 may further provide the central controller 199 with
volumetric flow into and out of the processing container 120. In an
embodiment, the inlet 130 is configured with an inlet flow meter
138 responsive to solution flow rate into the processing container
120. Similarly, the outlet 140 is configured with an outlet flow
meter 148 responsive to solution flow rate out of the processing
container 120. The central controller 199 is configured to process
data received from the inlet flow meter 138 and the outlet flow
meter 148 to assess volumetric change of the oocytes, embryos or
blastocysts 10 during processing. For instance, the flow rate of
the processing solution through the membrane 125 changes in
response to the change in volume of the oocytes, embryos or
blastocysts 10 during the cryopreservation process. The central
controller 199 monitors the change in solution flow rate and may
apply the information to control the cryopreservation process. The
flow rate data may further be stored in the memory unit and
associated with a particular oocyte, embryo or blastocyst batch for
subsequent retrieval and processing indicative of oocyte, embryo or
blastocyst viability.
[0078] The one or more sensors 198 may also measure the structural
state of the oocytes, embryos or blastocysts 10 within the
processing container 120. For example, a sensor 198 may be
configured to measure sphericity of the oocytes, embryos or
blastocysts 10 throughout the cryopreservation process. Sphericity
is a measure of the roundness of the oocyte, embryo or blastocyst
10 and may be defined by the ratio of the surface area of a sphere,
having a volume equal to the oocyte, embryo or blastocyst volume,
to the surface area of the oocyte, embryo or blastocyst. Sphericity
may also be approximated by circularity of the oocyte, embryo or
blastocyst. Volume and surface area of the oocyte, embryo or
blastocyst 10 can be determined from measurement systems known in
the art such as ultrasound and optical imaging systems. The central
controller 199 monitors data indicative of the sphericity of the
oocytes, embryos or blastocysts 10 during processing and may apply
the information to control the cryopreservation process. The
sphericity data may further be stored in the memory unit and
associated with a particular oocyte, embryo or blastocyst for
subsequent retrieval and processing indicative of oocyte, embryo or
blastocyst viability. For example, prior to fertilization,
sphericity data for a plurality of oocytes may be consulted to aid
the selection of likely fertilization candidates. Factors which may
be utilized in calculating the composite score include, but are not
limited to, volume change, sphericity, morphology of the oocyte and
zona pelucida separately, analysis of the cell wall, and for
oocytes specifically, a measure of the spindle, which may be
performed, for example, with an OOSIGHT.TM. optical instrument from
Cambridge Research & Instrumentation Inc. (CRI) of Woburn,
Mass.
[0079] In an embodiment, a storage device 197 is coupled to the
central controller 199. The storage device 197 is configured to
store information received from the central controller 199
including information received from the sensors 198. The storage
device 197 may collocated with the central processor. In another
embodiment, the storage device 197 may be located remotely. Where
the storage device 197 is remotely located, it may be adapted to
store information from one or more cryopreservation systems 100.
The storage device 197 may further be configured to accept and
store information indicative of the oocytes, embryos or blastocysts
processed in the cryopreservation system 100 such as identification
information. The storage device 197 is capable of associating the
oocyte, embryo or blastocyst information with the information
received from the central controller 199. The storage device 197
may further be configured to accept and store external information.
The information stored in the storage device 197 is retrievable for
processing and analysis. In an embodiment, information regarding
oocytes, embryos or blastocysts processed in the cryopreservation
system is retrieved for assessment of viability to select a subset
of oocytes, embryos or blastocysts for reanimation from a
population of available oocytes, embryos or blastocysts. For
instance, information related to the processing parameters, oocyte,
embryo or blastocyst volume and sphericity, and imagery of one or
more oocytes, embryos or blastocysts is retrieved and assessed to
assist in isolating a subset of oocytes, embryos or blastocysts.
The system may also generate a composite score indicative of the
overall quality of the oocyte, embryo or blastocyst for ranking and
selection of candidates.
[0080] The operation of the cryopreservation system 100 may be
controlled in various manners in accordance with a desired
cryopreservation or reanimation process. For example, in an
embodiment, the central controller 199 effects sequential flowing
of the solutions into the processing container 120. In this regard,
the central controller 199 may control the valves and or gas flow
such that the processing container 120 is first filled with
Solution I and, after a predetermined time, the processing
container 120 is emptied. The process may be repeated with each of
the other solutions.
[0081] In another embodiment, the fluid environment of the oocytes,
embryos or blastocysts is gradually altered to minimize shock to
the oocytes, embryos or blastocysts. In this regard, the central
controller 199 may first fill the processing container 120, 220,
600, 650, or 680 with a first solution. After a predetermined time,
the first solution may be gradually removed while a second solution
is supplied to the processing container 120. Other solutions may be
gradually added or removed in accordance with a desired process
parameters. Similarly, if solution components are used, the various
solution components may be dispensed to achieve a high degree of
control of the solution composition. Addition of the solutions or
solution components may be fully automated and based on a
predefined solution protocol. The predefined solution protocol may
optionally be modified during processing in response to information
received from the sensors 198 and processed by the central
controller 199. By controlling the inflow of the individual
solutions and or solution components into and the outflow from the
processing container 120, the oocytes, embryos or blastocysts are
exposed to a continuously changing concentration of cryoprotectant
and dehydrating components over the course of the cryopreservation
process. The continuous change in concentrations may further be
combined with continuous control of the solution temperature. The
process parameters of the cryopreservation system 100 are thereby
optimized for rapid removal of aqueous components from the oocytes,
embryos or blastocysts 10 and replacement with cryoprotectants.
[0082] Referring to FIGS. 3A and 3B, cryopreservation systems
according to another embodiment of the present invention are
illustrated. The cryopreservation systems illustrated in FIGS. 3A
and 3B are similar to that illustrated in FIG. 2 and described
above, but include an intermediate mixing container 220a. Thus, the
cryopreservation systems of FIGS. 3A and 3B include a processing
container 220 or 650 configured to house the oocytes, embryos or
blastocysts 10 therein. Solutions I, II, III, and IV or the
solution components are directed through a manifold 490 into the
intermediate mixing container 220a from the plurality of reservoirs
250, 260, 270, and 280. The plurality of reservoirs 250, 260, 270,
and 280 are coupled to manifold 490 as described above with the
corresponding coupling connections. Alternatively, the single
reservoir 300/301 may used in place of the plurality of reservoirs
250, 260, 270, and 280 and coupled to the manifold 490 with a
single coupler. As noted above, the flow of the solutions or
solution components is controlled by corresponding valves 252, 262,
272, and 282, respectively. Alternatively, as described above, flow
of the solutions or solution components may be controlled via gas
supplied to the plurality of reservoirs 250, 260, 270, and 280, or
the sub-compartments of the single reservoirs 300/301.
[0083] In the cryopreservation systems illustrated in FIGS. 3A, and
3B, the fluid provided to the processing container 220/650 is mixed
(and conditioned, if necessary) prior to exposing the oocytes,
embryos, or blastocysts to the fluid. Thus, drastic changes to the
fluid environment of the oocytes, embryos, or blastocysts are
avoided. The solutions I, II, III, and IV or the solution
components are allowed to mix in the intermediate mixing container
220a, and the mixed fluid is directed to the processing container
220 or 650 In the embodiment illustrated in FIG. 3A, the fluids are
mixed with an impellor mixer 410. Alternative mixing structures,
including a magnetic stirring bar, an integrated baffle, or other
mixing structure known in the art can be substituted or used in
combination with the impellor mixer 410.
[0084] Flow out of the intermediate mixing container 220a is
regulated by an intermediate valve 438 and/or an intermediate pump
435. The intermediate valve 438 and the intermediate pump 435 are
controllable by the cryopreservation system 100. The inlet 430 may
include a flow meter 432 responsive to the solution flow rate into
the processing container 650. Alternatively, as described above,
the processing container 120 may be used in place of the processing
container 650. A thermal controller 224 configured to control the
temperature of the fluid in the intermediate mixing container 220a
is optionally included. Similarly, the processing container 120/650
may be configured with a temperature controller 624 to control the
temperature therein.
[0085] Fluid is directed out of the processing container 650
through one or more outlets 670 and out flow is controlled by one
or more corresponding valves 648. The one or more corresponding
valves 648 are controllable by the cryopreservation system 100.
Flow rate out of the processing container 670 and through the one
or more outlets 670 is monitored by one or more corresponding flow
meters 642.
[0086] In the embodiment illustrated in FIG. 3B, flow of the mixed
fluid from the intermediate mixing container 220a to the processing
container 220 is achieved by allowing fluid to overflow from the
intermediate mixing container 220a into the processing container
220. The inlet valve 232 controls the flow of the solutions into
the intermediate mixing container 220a. Fluid is directed out of
the processing container 220 through an outlet 240 and out flow is
controlled by an outlet valve 242. Further, a thermal controller
224 is provided to control the temperature of the fluid in one or
both of the intermediate mixing container 220a and the processing
container 220.
[0087] FIGS. 7 and 8 illustrate exemplary solution concentration
profiles for preservation processes that may be carried out with a
cryopreservation system in accordance with an embodiment of the
present invention. FIGS. 9 and 10 illustrate exemplary solution
concentration profiles for reanimation processes that may be
carried out with a cryopreservation system in accordance with an
embodiment of the present invention. With reference to FIGS. 7-10,
concentrations of cryoprotectant and dehydrant components are
illustrated in relation to process time. In FIGS. 7-10,
concentrations of propylene glycol and sucrose are illustrated by
way of example. However, additional embodiments may encompass
different concentration profiles and or different or additional
components. For preparation for cryopreservation, the method may
include steps in which the concentration of the cryoprotectant
components is increased from about 0.0 M to about 1.5 M, and
wherein the concentration of the dehydrating components of the
fluid flowing into the processing container is increased from about
0.0 M to about 0.3 M. For reanimation, the method may include steps
in which the concentration of the cryoprotectant components of the
two or more fluids flowing into the processing container is
decreased, and wherein a concentration of the dehydrating
components of the two or more fluids flowing into the processing
container is decreased. For reanimation, the method may include
steps in which the concentration of the cryoprotectant components
is decreased from about 1.5 M to about 0.0 M, and wherein the
concentration of the dehydrating components of the fluid flowing
into the processing container is decreased from about 0.3 M to
about 0.0 M.
[0088] The methods and systems presented herein have been described
for the cryopreservation of oocytes, embryos or blastocysts.
However, one skilled in the art will appreciate that the above
systems and methods are adaptable to the reanimation of oocytes,
embryos, and blastocysts cryopreserved through the described
methods or by other cryopreservation methods known in the art.
[0089] Various embodiments described herein are described in the
general context of method steps or processes, which may be
implemented in an embodiment by a computer program product,
embodied in a computer-readable medium, including
computer-executable instructions, such as program code, executed by
computers in networked environments. A computer-readable medium may
include removable and non-removable storage devices including, but
not limited to, Read Only Memory (ROM), Random Access Memory (RAM),
compact discs (CDs), digital versatile discs (DVD), etc.
[0090] Embodiments of the present invention may be implemented in
software, hardware, application logic or a combination of software,
hardware and application logic. The software, application logic
and/or hardware may reside, for example, on a chipset, a memory
device or a processor.
[0091] While particular embodiments of the present invention have
been disclosed, it is to be understood that various different
modifications and combinations are possible and are contemplated
within the true spirit and scope of the appended claims. There is
no intention, therefore, of limitations to the exact abstract and
disclosure herein presented. The features of the embodiments
described herein may be combined in all possible combinations of
methods, apparatus, modules, systems, and computer program
products.
* * * * *